All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Trends in mass spectrometry

June 1, 2006
By Taia Ergueta
News
Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-06-01-2006
Volume 18
Issue 6

To fully optimize MS performance, corresponding enhancements are required in the other functional components of the integrated LC/MS platform.

Mass spectrometry (MS) is seen by many as a primary detection technology in drug discovery and development as well as in pharmaceutical QA/QC. Molecular mass is arguably the most broadly discriminative analytical parameter. Conjoined with LC retention time, it provides a distinctive signature for each analyte across the broad sweep of molecular entities. In addition, the ability to measure relative abundance also makes MS a first-order tool for quantification. Despite its large and long-standing contributions, MS technology has not fully met modern pharma application needs.

In target discovery, for the selectivity necessary to discern individual molecular signatures, mass accuracy is key. For picking up low-abundance biomarkers indicative of a pathway or metabolic response an ultra-low level of detection (LOD) is desired. This has only been available from very high priced MS.

In drug discovery, the focus has traditionally been on speed and throughput. A brute force approach to the workflow has made it possible to generate and then rapidly evaluate large numbers of molecular candidates for potency against multiple screens. Over time, however, this approach has yielded diminishing returns and increasing operational costs.

For QA/QC, with its massive and increasing processing load, throughput will always be issue number one. Add to that the need for better sensitivity, robust and repeatable performance, and ease-of-use.

A new generation of MS tools

New MS solutions to the challenges described above are now emerging. They are derived from key advances such as:

  • 2 ppm mass accuracy LC/MS TOF

  • multimode source with simultaneous ESI and APCI ion generation

  • ultra sensitive next generation triple quad MS/MS

  • fundamental advances in data mining, quantification and reporting software.

These advances have given rise to new levels of performance, ease-of-use and throughput for many applications. In some cases, they are facilitating entirely new work flows.

Examples of such application shifts include pre-empting time consuming biomarker identification analyses with profiling-based methodologies in an effort to reduce the number of required IDs to be preformed. Such proteomic and metabolomic profiling techniques are the direct result of new high mass accuracy LC/MS TOF instrumentation that can give uniqueness to literally thousands of analytes in a single analysis. Mass accuracies in the 1–2 ppm level that extend over a wide analyte concentration are the result of sophisticated calibration and reference mass correction algorithms that have been realized via simple software control. When the application centres on the small or large molecule confirmation, the same features result in a completely automated "walk up analysis", wherein a user places samples in the instrument's autosampler, selects the method, initiates the run command, and in due course receives the results in a preselected report format.

Multimode ionization source technology has improved many screening techniques as well as applications in QA/QC. Multimode ionization gives greater universality by simultaneously generating ions by both ESI and APCI processes under a very broad range of separation flow-rate conditions. These advances eliminate the need for replicate analysis, resulting in higher throughput.

To address the need for cost-effective performance, ruggedness and ease-of-use, there are new generation instruments such as the triple quadrupole MS with femtogram-level sensitivity. Intended for a variety of pharma analytical applications, these machines are exceptionally reliable and are supported by easy-to-learn operating and end user customizable reporting software. Innovations of this sort are particularly welcome in quantification of drug candidates from early in vitro studies through clinical trials where the requirement for high throughput remains unabated and where challenges such as sample preparation, formulation complexity and detection limits are becoming more demanding.

New developments complete the picture

To fully optimize MS performance, corresponding enhancements are required in the other functional components of the integrated LC/MS platform. Here too, there are exciting developments pushing the performance envelope. New rapid-resolution HPLC systems capable of order-of-magnitude increases in throughput have recently been introduced. On another technology front, the microfluidic HPLC chip is revolutionizing column chromatography. The chips are designed to integrate with and maximize the entire continuum of LC/MS performance. Benefits include easier operation, greater application flexibility, increased uptime and lower operational costs.

Ultrasensitive and diverse MS technology, high throughput, rapid-resolution LC, microfluidic chips and new informatics — these are the key components of emerging instrument platforms that will support the growing suite of analytical applications across the pharma enterprise.

Taia Ergueta is general manager for proteomics, metabolomics and LC/MS at Agilent Technologies, USA.

Articles in this issue

i8_t-359836-1408686433114.jpg
Evolving concepts in plant design: part 1
i4-359837-1408686428710.jpg
A guide for testing biopharmaceuticals Part II: acceptance criteria and analytical method maintenance
i1-359840-1408686406274.jpg
Trends in mass spectrometry
Generating and protecting knowledge with electronic laboratory notebooks
i4-359835-1408686438745.jpg
Spotlight
i4-359838-1408686414687.jpg
Criticality of functional excipients and decoding methods during generic product development
Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


low angle view of marble dome of United States Capitol building in Washington DC with blue sky and visible architecture features | Image Credit: © Philip - stock.adobe.com

9 Implications of Trump’s Tax-Cut and Spending Bill for the Bio/Pharmaceutical Industry

Christopher Cole
July 7th 2025
Article

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting strategy across the bio/pharmaceutical industry.


Document Review and Quality Control Concept. Document with a checkmark, quality assurance, and process control. auditing, compliance, verification, data inspection, and business workflow management. | Image Credit: © Supatman - stock.adobe.com

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

Diana Russo
July 4th 2025
Article

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.

Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


low angle view of marble dome of United States Capitol building in Washington DC with blue sky and visible architecture features | Image Credit: © Philip - stock.adobe.com

9 Implications of Trump’s Tax-Cut and Spending Bill for the Bio/Pharmaceutical Industry

Christopher Cole
July 7th 2025
Article

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting strategy across the bio/pharmaceutical industry.


Document Review and Quality Control Concept. Document with a checkmark, quality assurance, and process control. auditing, compliance, verification, data inspection, and business workflow management. | Image Credit: © Supatman - stock.adobe.com

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

Diana Russo
July 4th 2025
Article

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.